Filing Flows › Comparisons › ALGS vs XFOR
Aligos Therapeutics vs X4 Pharmaceuticals: ALGS and XFOR compared
Aligos Therapeutics is the larger company: $2.8M of revenue in its latest quarter (Q3 2026) against $2.8M for X4 Pharmaceuticals (Q3 2026). Aligos Therapeutics is growing faster (+282% against +75% a year earlier). X4 Pharmaceuticals is more profitable, with an operating margin of -714.0% against -773.5%.
Where the money goes: ALGS and XFOR
Aligos Therapeutics (ALGS) · Q3 2026
Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.
X4 Pharmaceuticals (XFOR) · Q3 2026
X4 Pharmaceuticals, Q3 2026: revenue $2.8M (+75% year over year), operating margin -714.0%, net loss $20.2M, operating cash flow −$20.2M. The chart follows the revenue to costs, profit and cash.
| Aligos Therapeutics (ALGS) | X4 Pharmaceuticals (XFOR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $2.8M | $2.8M |
| Revenue growth, Y/Y | +282% | +75% |
| Operating margin | -773.5% | -714.0% |
| Net earnings | −$21.9M | −$20.2M |
| Net margin | -772.4% | -721.4% |
| Operating cash flow | $1.5M | −$20.2M |
| Market value | $55.7M | $424M |
| P/E | — | 1.9× |
| Analysts’ mean target | $52.38 | $11.60 |
Questions
Which is bigger, Aligos Therapeutics or X4 Pharmaceuticals?
Aligos Therapeutics is the larger company: $2.8M of revenue in its latest quarter (Q3 2026) against $2.8M for X4 Pharmaceuticals (Q3 2026).
Is Aligos Therapeutics or X4 Pharmaceuticals growing faster?
Aligos Therapeutics is growing faster (+282% against +75% a year earlier).
Which is more profitable, Aligos Therapeutics or X4 Pharmaceuticals?
X4 Pharmaceuticals is more profitable, with an operating margin of -714.0% against -773.5%.
More: Aligos Therapeutics earnings · how Aligos Therapeutics makes money · X4 Pharmaceuticals earnings · how X4 Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.